Am. J. Respir. Crit. Care Med., Volume 161, Number 4, April 2000, 1252-1255

High Incidence of Posttransplant Lymphoproliferative Disease in Pediatric Patients with Cystic Fibrosis

ALAN H. COHEN, STUART C. SWEET, ERIC MENDELOFF, GEORGE B. MALLORY Jr., CHARLES B. HUDDLESTON, MADELEINE KRAUS, MICHAEL KELLY, ROBERT HAYASHI, and MICHAEL R. DEBAUN

Georgia Pediatrics, Pulmonology Associates, Atlanta Georgia; and Divisions of Cardiothoracic Surgery, Pathology, Hematology/Oncology, and Allergy and Pulmonary Medicine, Washington University School of Medicine, St. Louis Children's Hospital, St. Louis, Missouri

A major cause of morbidity and mortality following lung transplantation is posttransplant lymphoproliferative disease (PTLD). In a retrospective cohort analysis of pediatric patients, we evaluated the risk factors associated with PTLD in 128 first-time lung transplant recipients from 1990 to 1997. The greatest risk factor for PTLD was a diagnosis of cystic fibrosis (CF). Of the 16 patients in our analysis who had PTLD, 13 had a diagnosis of CF (odds ratio [OR]: 5.8; confidence interval 95% [CI]: 1.6 to 21.4). Because of the high frequency of PTLD in patients with CF (13 of 61; 23%), we performed a retrospective cohort analysis in which patients with CF and PTLD were designated as cases and patients with CF and without PTLD served as controls. In patients with CF, the only risk factor associated with PTLD was two or more episodes of acute rejection within 3 mo after transplantation (OR: 11.0; 95% CI: 2.7 to 55.7). Age, recipient Epstein-Barr virus or cytomegalovirus status, induction with antilymphocyte globulin or antithymoyte globulin (ATG), or use of ATG or OKT3 for acute rejection episodes were not risk factors for PTLD. The high frequency of PTLD in the subgroup of patients with two or more episodes of graft rejection within 2 mo after lung transplantation was unexpected, and warrants further investigation in prospective clinical studies and basic laboratories.

This article has been cited by other articles:

				D. Hadjiliadis Special Considerations for Patients With Cystic Fibrosis Undergoing Lung Transplantation Chest, April 1, 2007; 131(4): 1224 - 1231. [Abstract] [Full Text] [PDF]

				M. E. Halkos, J. I. Miller, K. P. Mann, D. L. Miller, and A. A. Gal Thoracic Presentations of Posttransplant Lymphoproliferative Disorders Chest, December 1, 2004; 126(6): 2013 - 2020. [Abstract] [Full Text] [PDF]

				G.B. Mallory and T.L. Spray Paediatric lung transplantation Eur. Respir. J., November 1, 2004; 24(5): 839 - 845. [Abstract] [Full Text] [PDF]

				P. Maisonneuve, S. C. FitzSimmons, J. P. Neglia, P. W. Campbell III, and A. B. Lowenfels Cancer Risk in Nontransplanted and Transplanted Cystic Fibrosis Patients: A 10-Year Study J Natl Cancer Inst, March 5, 2003; 95(5): 381 - 387. [Abstract] [Full Text] [PDF]

				M. J. Brenner, T. H. Tung, J. N. Jensen, and S. E. Mackinnon The Spectrum of Complications of Immunosuppression: Is the Time Right for Hand Transplantation? J. Bone Joint Surg. Am., October 10, 2002; 84(10): 1861 - 1870. [Full Text] [PDF]

				M. J. TOBIN Chronic Obstructive Pulmonary Disease, Pollution, Pulmonary Vascular Disease, Transplantation, Pleural Disease, and Lung Cancer in AJRCCM 2000 Am. J. Respir. Crit. Care Med., November 15, 2001; 164(10): 1789 - 1804. [Full Text] [PDF]